




RealRate

# PHARMACEUTICAL 2019

## International Stem Cell CORP Rank 236 of 363





RealRate

# PHARMACEUTICAL 2019

## International Stem Cell CORP Rank 236 of 363



The relative strengths and weaknesses of International Stem Cell CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of International Stem Cell CORP compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 125% points. The greatest weakness of International Stem Cell CORP is the variable Assets, Current, reducing the Economic Capital Ratio by 126% points.

The company's Economic Capital Ratio, given in the ranking table, is 34%, being 2.6% points below the market average of 37%.

Input Variable	Value in 1000 USD
Assets, Current	3,770
Cost of Goods Sold	4,069
Intangible Assets	2,674
Liabilities, Current	5,077
Liabilities, Non-Current	0
Other Assets	883
Other Compr. Net Income	0
Other Expenses	2,631
Other Liabilities	182
Other Net Income	1,343
Other Revenues	11,089
Property and Equipment	469
Research and Development	2,396
Selling, General and Administrative Expense	5,467

Output Variable	Value in 1000 USD
Assets	7,796
Liabilities	5,259
Expenses	14,563
Revenues	11,089
Stockholders Equity	2,537
Net Income	-2,131
Comprehensive Net Income	-2,131
Economic Capital Ratio	34%